TAKE Limited Q1 FY27: revenue Rs 30.37 Cr, net profit Rs 1.06 Cr

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

TAKE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹23.25

prior close

₹23.94

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+1.1% vs market

Healthcare Research Analytics & Technology peers, median of 5sector-0.8%+2.2% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 2.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.2

15m

-1.0

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.4+1.1-0.8+2.2

Next day

+2.1+0.5+1.6-1.7+3.8

+3.1+0.6+2.5-1.5+4.6

-0.4+0.7-1.2-1.4+1.0

+0.8+1.1-0.3+0.1+0.7

-1.5+0.5-2.0-2.6+1.1

-10.8+1.3-12.0-0.0-10.7

15d

-40.4+0.5-40.9+5.3-45.7

-20.5-0.8-19.6-2.0-18.5

-45.4-0.9-44.5-8.3-37.1

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

TAKE Limited reported a sharp Q1 FY27 turnaround. Consolidated revenue surged to Rs 30.37 Cr from nil a year ago, with net profit of Rs 1.06 Cr versus a Rs 91 lakh loss in Q1 FY26. Standalone revenue jumped to Rs 11.97 Cr with profit of Rs 96.83 lakhs. Finance costs fell 99.6% YoY to near zero, reflecting debt elimination. EPS turned positive at Rs 0.07. Auditor issued an unqualified limited review. The company also announced a strategic entry into biohacking, nutraceuticals, and digital longevity markets.

Likely market impact

Return to profitability, debt-free balance sheet, and new longevity segment add growth narrative; small absolute profit base means results remain early-stage.